효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 ( ) 가천의대길병원내분비대사내과
|
|
- Adelia Hawkins
- 5 years ago
- Views:
Transcription
1 효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 ( ) 가천의대길병원내분비대사내과 박이병
2 내용 배경 경구혈당강하제의병합이왜필요한가? (WHY?) 경구혈당강하제의병합은언제시작하나? (WHEN?) 경구혈당강하제의병합은어떻게하는것이좋은가?(HOW) 맺음말
3 배경 : drugs for treating diabetes In 1995 : sulfonylureas, insulin Currently 11 classes : sulfonylureas, meglitinides, glucagon-like like peptide-1 (GLP-1) receptor agonists, biguanides, amylin analogue, thiazolidinediones, bromocriptine, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 4(DPP4) (DPP-4) inhibitors, colesevalam l (a bile-acid id sequestrant), and insulins Newer agents : more costly, some are only approved as adjunctive Combination pattern - 5.6% during during % taking three or more classes
4 경구혈당강하제의병합이왜 필요한가? (WHY)
5 UKPDS 10-Year Follow-up 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes Rury R. Holman, F.R.C.P., Sanjoy K. Paul, Ph.D., M. Angelyn Bethel, M.D., David R. Matthews, F.R.C.P., and H. Andrew W. Neil, F.R.C.P. UKPDS 80 (N Engl J Med 2008;359; ) N Engl J Med 2008, 359:
6 조기혈당조절의 Legacy Effect UKPDS 연구종료후연장된추적관찰에서심근경색의위험과모든원인으로인한사망을줄이는것으로나타남 시험완료 8.5년 ( 중앙값 ) 후추적관찰시 모든종말점 모든당뇨병관련종말점 RRR: 12% 9% p: 미세혈관질환 RRR: 25% 24% p: 심근경색 RRR: 16% 15% p: 모든원인사망율 RRR: 6% 13% p:
7 복합위험인자치료 (Steno-2) :13 년추적관찰 Glycate edbin Hemoglob (%) 전통치료 집중치료 Chol /dl) Total (mg/ 300 전통치료 집중치료 lic BP mhg) Systo (mm 전통치료 집중치료 Chol g/dl) LDL (mg 전통치료 집중치료 Diast tolic BP (mm mhg) 전통치료 Trigly ycerides (mg g/dl) 집중치료 100 집중치료 추적관찰 ( 년 ) 추적관찰 ( 년 ) 전통치료 Gaede P et al. N Engl J Med 2008;358:
8 복합위험인자치료 (Steno-2) 5년의추적관찰기간중두군모두에서유사한복합위험인자관리가이루어졌으나, 임상적이익은이전에집중치료를받은환자들에서만증가되었음 사망의누적적발생률 (%) 위험군환자집중치료 80 전통치료 P = 0.02 P < 전통치료 추적관찰 ( 년 ) 집중치료 모든심혈관질환의누적발생률 (%) 위험군환자집중치료 80 전통치료 80 전통치료 집중치료 추적관찰 ( 년 ) Gaede P et al. N Engl J Med 2008;358:
9 Intensive control may reduce diabetic complications (meta-analysis) analysis) UKPDS PROactive ADVANCE VADT ACCORD 33,040 patients, follow-up 4.95 years Duration of T2DM 8 years mean HbA1c 7.8% at baseline 6.6%(INT) VS. 7.5%(STD) after follow-up Intensive glucose control : 17% reduction in non-fatal myocardial infarction : 15% reduction in coronary heart disease : 7% reduction in stroke (NS) : no increase on all-cause mortality Lancet 2009; 373:
10 Exposal of hyperglycemia may increase risk of diabetic complications cat o VADT in the context of the natural history of Type 2 diabetes Method: Intensive treatment (HbA1c < 6%) vs. conventional treatment (HbA1c < 9%) Stefano Del Prato : th ADA. Treatment - When Do We Start? What Do We Attack?
11 Early and Intensive treatment ACCORD, ADVANCE, VADT in 2008 Prematurely terminated UKPDS 10 year follow-up in 2008 Legacy effect The meta-analysis in % risk reduction of CV event & no effect on mortality Diabetes & Metabolism 36 (2010) 86 87
12 경구혈당강하제의병합은언제 시작하나? (WHEN)
13 Decline in β-cell function is associated with loss of glycemic control 9 Conventional HbA 1c (%) 8 7 Intensive % = normal range of HbA 1c Years from randomization UKPDS 33. Lancet 1998; 352:
14 ADOPT - HbA1c over time Rosiglitazone vs Metformin (-0.22 to -0.05), P=0.002 Rosiglitazone vs Glyburide ( to -0.33), P<0.001 NEJM 2006, 355,
15 The Practical Evidence of Antidiabetic Monotherapy Study (PEAM) : monotherapy in Drug-Naïve in Korea Diabetes Metab J Feb;35(1):26-33.
16 Earlier Use of Combination Therapy may achieve e target goal 10 Diet and exercise OAD* monotherapy Early combination approach OAD combinations OAD up-titration OAD + basal insulin Hb ba 1c (%) 9 8 OAD + multiple daily insulin injections 7 6 Duration of diabetes Del Prato S et al Int J Clin Pract 2005;59:
17 Control Hyperglycemia Needs for Early Combination Evidence based Medicine
18 대한당뇨병학회권고안 HbA1c 목표 < 6.5% 치료적생활습관교정 < 8.0% % > 10% 단독요법 * 조기병합요법또는인슐린요법 2~6 개월내목표에도달하지못하면 인슐린요법 + 경구혈당강하제 다른약제추가 3 제요법 인슐린추가다요소인슐린요법 ± 경구혈당강하제 * 1차치료 : 메트포르민을우선권하나환자의특성에따라다른약제선택도가능 ( 설폰요소제, DPP-4 억제제, 티아졸리딘디온, 알파글루코시다아제억제제, 메글리티나이드 ) 2차치료 : GLP-1 analogue 대한당뇨병학회, 당뇨병진료지침 2011
19 제2형당뇨병에서고혈당의관리 : 치료시작과조절에대한컨센서스알고리즘 미국당뇨병학회 (ADA)(7% 이하 ) 와유럽당뇨병학회 (EASD) 의 Consensus Statement Tier 1: 진단시 충분히입증된핵심치료법 생활습관 + metformin + 기저인슐린 생활습관 + metformin + 강화인슐린 생활습관 + metformin 생활습관 + metformin + Sulfonylurea 1 단계 2 단계 3 단계 Tier 2: 충분히입증되지않은치료법 생활습관 + metformin + pioglitazone 생활습관 + metformin + GLP- 1 agonist 생활습관 + metformin + pioglitazone + Sulfonylurea 생활습관 + metformin + 기저인슐린 Nathan DM et al. Diabetes Care 2009;32:
20 Glycemic Control Algorithm, Endocr Pract. 2009;15(No )
21
22
23 경구혈당강하제의병합은어떻게 시작하나? (HOW)
24 *Comparison with hypoglycemic drugs Monotherapy vs. monotherapy Monotherapy vs. combination Combination vs. combination - HbA1c - weight - lipid profile - hypoglycemia and side effects - C-V risk and mortality, etc.
25 Combination vs. combination
26 Monotherapy versus Monotherapy Most oral diabetes medications had similar efficacy in achieving reductions in HbA1c, with absolute reduction by around 1 percent compared with baseline values. ADOPT
27 Combination Therapy versus Monotherapy All combination therapies were better at reducing HbA1c than monotherapy regimens, with between-group differences of about 1 percent. The strength of evidence was graded high for metformin versus metformin plus thiazolidinediones, and metformin versus metformin plus sulfonylureas, and graded moderate for metformin versus metformin plus DPP-4 inhibitors.
28 Combination Therapy Versus Combination Therapy The combination of metformin + thiazolidinedione had similar efficacy in reducing HbA1c compared to the combination of metformin + sulfonylurea, with moderate strength of evidence. Nine other combination therapy comparisons had low strength of evidence, making it difficult to draw firm conclusions. However, the majority showed similar efficacy in reducing HbA1c. Five combinations showed similar efficacy in reducing HbA1c: 1) metformin + repaglinide vs. metformin + thiazolidinedione, 2) metformin + sitagliptin vs. metformin + thiazolidinedione, 3) metformin + sulfonylurea vs. metformin + DPP-4 inhibitor, 4) metformin + thiazolidinedione vs. metformin + GLP-1 agonist, 5) metformin + GLP-1 agonist vs. metformin + basal insulin
29 경구혈당강하제선택에있어서고려사항 환자의연령 ( 여명, 저혈당의위험성 ) 동반질환, 합병증 당뇨병진단시기 현재혈당조절상태 약제별작용기전및장단점 경제적측면 부작용없이혈당조절 * 보험기준에준용해서처방은당연필수!
30 경구혈당강하제의병합요법 다른계열의약제를추가 약제의작용기전을고려 조절중당화혈색소가 65% 6.5% 를초과하면 2 차 ( 또는 3 차 ) 약제를추가 진단당시당화혈색소가 8% 를초과하면조기에병합요법을고려 병합요법실패시인슐린치료가추천되나환자의특성과상황에따라약제변경, 3제병합요법도고려해볼수있다.
31 경구혈당강하제의특성
32
33
34 다양한병합요법 (1) 설폰요소제와메트포르민 - 인슐린분비능및인슐린감수성동시에개선 식후고혈당이문제될경우 : meglitinide, a-glucosidase inhibitor, GLP-1 receptor agonist나 DPP IV inhibitor의추가 설폰요소제 + 알파글루코시데이즈억제제 : 설폰요소제사용하면서 식후만조절이안될경우 비아나이드제 + 티아졸리딘디온계 : - 메트포르민단독요법으로혈당조절이잘되지않은경우, - 비만한환자나인슐린저항성이많은경우
35 다양한병합요법 (2) DPP IV inhibitor 의경우는다양한병합처방이가능 - 설폰요소제, 메트포민, 티이졸리딘디온계, 인슐린가병합가능 - DPP IV inhibitor + 메트포민병합 : 당화혈색소 1% 이상을감소, 저혈당없이체중을조절할수있으며베타세포의기능을보전하는등의다양한치료효과가증명되고있음 설폰요소제 + 메트포르민병합요법으로조절되지않은경우 - 알파글루코시다제억제제, 티아졸리딘디온계, DPP IV inhibitor 추가 설폰요소제 + 메글리티나이드 : 병용금기 메글리티나이드 + 알파글루코시다아제 : 작용기전을다르나둘다식후혈당조절을목표로하여병합하지말라는권고안도있으나환자에따라서병용가능함
36 다양한병합요법 (3) 부작용고려 저혈당이빈번한경우 : 설포닐요소제중단 소화기계부작용 : 메트포민, 알파글루코시데이즈억제제금지 비만, 심장질환동반된경우 : 티아졸린디온금지
37 고정복합제 설폰요소제 + 메트포르민 티아졸리딘디온 + 메트포르민 메트포르민 + DPP-4 억제제 * 최근에는 sitagliptin ti 과 simvastatin ti 의복합제 (Juvisync ) 미국 FDA 승인
38 맺음말 당뇨병합병증을예방하기위하여적절한혈당조절이필요하다. 혈당조절에적절하지못할경우, 경구혈당강하제를병합하거나조기에병합처방할수있다. 혈당강하제를병합할경우, 약제의특성과부작용등을고려해서처방한다. 보건복지부고시기준에맞게처방하는지혜가필요하다.
39 감사합니다!
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationEvidence-Based Glucose Management in Type 2 Diabetes
Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationCONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*
CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?
More informationGlycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationFixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University
Fixed dose combination for Trusted Diabetes Control By Lobna Farag Eltooy Head of Internal Medicine Department 1 Assiut University 3/18/2018 3/18/2018 3/18/2018 Diabetes Complications with Increasing HbA1c
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationMetabolic Karma. - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D
2014 ICDM Breakfast Symposium. Oct 18, 2014 Grand Hilton, Seoul Metabolic Karma - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D Department of Endocrinology and Metabolism, Hallym University
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know
Non Insulin Treatment of Type 2 Diabetes: What the PCP Needs to Know Martin J. Abrahamson, MD Senior Vice President for Medical Affairs Joslin Diabetes Center Associate Professor of Medicine Harvard Medical
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationAACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM. Sherwin D Souza, MD, FACE
AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM Sherwin D Soza, MD, FACE Prediabetes Treatment Algorithm T2DM = type 2 diabetes mellits BP = blood pressre CVD = cardiovasclar disease
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationLecture title. Name Family name Country
Lecture title Name Family name Country Patricia B. Gatbonton, MD, FPCP, FPSEM Endocrinology, Diabetes & Metabolism When insulin is NOT an option Learning Objectives Define factors leading to uncontrolled
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationEffective Health Care
Number 8 Effective Health Care Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes Executive Summary Background Type 2 diabetes is characterized by insulin
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationThiazolidinedione Step Therapy Program
Thiazolidinedione Step Therapy Program Policy Number: 5.01.580 Last Review: 7/2018 Origination: 07/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationGlycemic control A combination of life style interaction and the use of drugs
Multifactorial management to reduce cardiovascular risk in patients with diabetes mellitus Glycemic control A combination of life style interaction and the use of drugs Eberhard Standl Munich Diabetes
More informationEnrique Caballero, MD Director, Latino Diabetes Initiative Joslin Diabetes Center Harvard Medical School
New Diabetes Treatments Embryonic Stem Cells (ESC) Ectoderm Mesoderm Enrique Caballero, MD Director, Latino Diabetes Initiative Joslin Diabetes Center Harvard Medical School ESC Endoderm Pancreas Islet
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACCORD (Action to Control Cardiovascular Disease and Diabestes), blood pressure goal, 74 ACEIs (Angiotensin-converting enzyme inhibitors),
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationTreatment of Type 2 Diabetes: What Have We Learned? AACE Diabetes Algorithm. ADOPT Trial 6/13/2012
Treatment of Type 2 Diabetes: What Have We Learned? Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering needed, patientspecific
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact DIABETES
More informationYes! Is Type 2 diabetes the same in kids as in adults? And No! Youth-onset type 2 diabetes 5/16/2018 LEST WE THINK THIS IS NOT AN IMPORTANT PROBLEM
Youth-onset type 2 diabetes PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DEPARTMENT OF ENDOCRINOLOGY CHILDREN S HOSPITAL COLORADO LEST WE THINK THIS IS
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Diabetes Update July 6, 2017 12:00pm 1:00pm Jennifer Pennock Holst, MD Endocrinology, Diabetes & Metabolism AHN Center for
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationJeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October Your DM patient is ready for discharge, now what?
Jeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October 2018 Your DM patient is ready for discharge, now what? Financial Disclosures None Objectives 1. Understand follow up patterns/capability of patients
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2011 BMI
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationCADTH Optimal use report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Optimal use report Volume 3, Issue 1D July 2013 Optimal Use Recommendations
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationTREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017
TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 Outline Review treatment algorithms from ADA/ EASD & ACE/AACE. Review positive
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationNew Drug Evaluation: Dulaglutide
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationDiabetes It s not just sugar
HeartWise 2014 April 11, 2014 Matthew A. Sauder, MD LG Health Physicians Diabetes and Endocrinology Diabetes It s not just sugar Objectives Review the link between diabetes and cardiovascular disease Discuss
More informationNew Drug Evaluation: lixisenatide injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationVolume : 05 Issue : 03 July-Sept Pages:
Middle East Journal of Applied Sciences Volume : 05 Issue : 03 July-Sept. 2015 Pages: 695-699 Efficacy and Safety of Vildagliptin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Poorly Controlled
More informationPharmacy Drug Class Review
June 1, 010 Pharmacy Drug Class Review Disclaimer: Specific agents may have variations Cardiovascular Impact of Diabetic Agents ACCORD, ADVANCE, VADT, UKPDS 10yr, PERISCOPE, PROactive Authored By: Lauren
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationUpdates in Diabetes Care
Updates in Diabetes Care Disclosures Nothing to disclose Pharmacist Objectives 1. List strategies for improving diabetes care 2. Understand benefits and risks associated with newer pharmacotherapeutic
More informationManagement strategies for diabetes Rupa Ahluwalia
Chapter 2 Management strategies for diabetes Rupa Ahluwalia Diabetes remains one of the biggest health challenges in the developed world, with a current prevalence of approximately 4% of the UK general
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More information